Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in Moderate-to-Severe COPD (AERIFY-2)
NCT04751487Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of itepekimab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Feb 2021; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04751487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751487.